Welcome to This Is MS!

     Modules
· Home
· Content
· Downloads
· Encyclopedia
· FAQ
· Feedback
· Forums
· Journal
· Private Messages
· Recommend Us
· Search
· Site_Map
· Stories Archive
· Submit News
· Surveys
· Top 10
· Topics
· Web Links
· Your Account

     Google
Google
Web
This is MS
These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS.

     Languages
Select Interface Language:


     Who's Online
There are currently, 62 guest(s) and 7 member(s) that are online.

You are Anonymous user. You can register for free by clicking here

     Next Step

From the creators of This is MS comes Experience Project

EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at Experience Project.

Get started by sharing your Multiple Sclerosis story.


     Donations

To remain unbiased, This is MS does not accept corporate sponsorships.

Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you!


ThisIsMS.com :: View topic - Conditions under which Tysabri will come back to market
 Forum FAQForum FAQ   SearchSearch   UsergroupsUsergroups   ProfileProfile   Log in to check your private messagesLog in to check your private messages   Log inLog in 


Conditions under which Tysabri will come back to market

 
Post new topic   Reply to topic    ThisIsMS.com Forum Index -> Tysabri (Antegren or Natalizumab)
View previous topic :: View next topic  
Author Message
OddDuck
Contributing Author


Joined: Jun 20, 2004
Posts: 1040
Location: Tennessee

PostPosted: Sun Apr 02, 2006 10:09 am    Post subject: Conditions under which Tysabri will come back to market Reply with quote

I posted this in another thread just now, but figured it might need it's own thread. This is a March 27th update regarding the return of Tysabri:

http://www.nationalmssociety.org/tysabri_march8.asp

Excerpt:

Quote:
"....Its key recommendations for approval include:

• Tysabri be made available only to patients who have enrolled along with their physicians in a mandatory registry program;

• Tysabri be made available only to patients diagnosed with relapsing MS;

• Tysabri could be considered appropriate for use in MS patients who experience relapses regardless of their degree of disability, so that even persons with no disability or severe disability would be eligible;

• Tysabri be given only at authorized infusion centers where the medical personnel have been trained in its proper use and in the risks of PML;

• Tysabri not be used in patients who have compromised immune systems or who are taking other immunosuppressive or immunomodulatory agents, with the possible exception of periodic steroids to treat relapses;

• prescribing information carry a “black box warning” concerning PML;

• prior to starting treatment, the physician complete a “patient checklist” to ensure that the patient meets all requirements for use of Tysabri; and

• prior to each infusion, the patient and infusion nurse complete a checklist to screen for symptoms suggestive of PML.

The advisory committee did not achieve consensus on any recommendation of whether Tysabri should be used as a “first-line” therapy or whether a patient must first be on another disease-modifying therapy that proved ineffective. ...."

Back to top
View user's profile Send private message
HarryZ
Family Elder


Joined: May 26, 2004
Posts: 1383
Location: London, ON, Canada

PostPosted: Mon Apr 03, 2006 6:27 am    Post subject: Re: Conditions under which Tysabri will come back to market Reply with quote

Deb,

This is the same drug that was rushed through the approval process and released to the general public last January (2005), wasn't it? Confused

Harry
Back to top
View user's profile Send private message Send e-mail
OddDuck
Contributing Author


Joined: Jun 20, 2004
Posts: 1040
Location: Tennessee

PostPosted: Tue Apr 04, 2006 11:59 am    Post subject: Reply with quote

Yep. Sure was, Harry! The one we were saying "Wait, wait! Slow down!"

Oh well, I'm used to not being listened to. Hence my last two divorces! Laughing
Back to top
View user's profile Send private message
better2gether
Family Elder


Joined: Dec 20, 2004
Posts: 188

PostPosted: Wed Apr 05, 2006 2:46 am    Post subject: Risk Control Plan Key To Natalizumab's Return Reply with quote

.
Risk Control Plan Key To Natalizumab's Return

ELIZABETH MECHCATIE (Senior Writer)

http://www.clinicalneurologynews.com/article/PIIS1553321206714534/fulltext
.
Back to top
View user's profile Send private message
Display posts from previous:   
Post new topic   Reply to topic    ThisIsMS.com Forum Index -> Tysabri (Antegren or Natalizumab) All times are GMT - 6 Hours
Page 1 of 1

 
Jump to:  
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum





We encourage you to also visit our Multiple Sclerosis story and support community on Experience Project. Experience Project is a vast and powerful community where people connect anonymously through life experiences. It's made by the same people who built This is MS, on the premise that no one life experience-- like having MS-- defines a person. It now covers over 2 million life stories. Find and share yours!

Experience Project: I have Multiple Sclerosis


Anonymous Confessions | Free Dream Interpretations | Ask Any Question
Site Map

This site does not offer medical advice. All treatment decisions should always be made with the full consent of your physician.


All logos and trademarks in this site are property of their respective owners. The comments are property of their posters, quoted articles are © referenced source, all the rest © 2002-8 by thisisMS.com.
PHP-Nuke Copyright © 2005 by Francisco Burzi. This is free software, and you may redistribute it under the GPL. PHP-Nuke comes with absolutely no warranty, for details, see the license.
Page Generation: 0.10 Seconds